|
|||||
|
|
The landscape of BCR-ABL mutations in patients with Philadelphia chromosome-positive leukaemias in the era of second-generation tyrosine kinase inhibitors |
|
| Authors: | Sheng-Hsuan Chien Hsueng-Mei Liu Po-Ming Chen Po-Shen Ko Jeong-Shi Lin Ying-Ju Chen Li-Hsuan Lee Liang-Tsai Hsiao Tzeon-Jye Chiou Jyh-Pyng Gau Muh-Hwa Yang Chun-Yu Liu |
| Affiliation: | 1. Division of Transfusion Medicine, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan;2. Department of Food and Science and biotechnology, National Chung Hsing University, Taichung, Taiwan;3. Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan Division of Hematology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan;4. Division of Transfusion Medicine, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan;5. Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan |
| Abstract: | |
| Keywords: | BCR-ABL chronic myeloid leukaemia log reduction mutation tyrosine kinase inhibitor |